Skip to content

SUIG SUIG Increase (Decrease) in Notes Receivables

Increase (Decrease) in Notes Receivables at other companies

CAVA Group logo
CAVA GroupCAVA
$424K
AptarGroup logo
AptarGroupATR
$335K+112%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$1.9M+15.2%
SUI
Sui Group Holdings Limited Common StockSUIG
$0+100%
Microvast Holdings, Inc. logo
Microvast Holdings, Inc.MVST
$3.28M-37.7%
UMH
UMH PropertiesUMH
$1.79M-47.8%

Other financials

Income statement

See full
Revenue$593.9K-23.7%
Operating income-$60.5M-10,890%
Net income-$70.9M-15,805%
EPS (diluted)-$0.88-1,357%

Balance sheet

See full
Cash & equivalents$5.0M+186%
Total debt$3.7K-66.3%
Total equity$100.8M+415%
Total assets$118.7M+498%

Cash flow

See full
Operating cash flow-$1.8M+50.6%

Valuation

See full
Market cap$93.84M-82.6%
P/S25.3×

Profitability

See full
Operating margin-8,777.7%
Net margin-9,073.3%

Returns & leverage

See full
Return on equity-560%
Debt / equity0.0×
Current ratio0.8×

Where this comes from

Reported directly by SUIG in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInNotesReceivables.

The official record: SUIG’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about SUIG's increase (decrease) in notes receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SUIG's increase (decrease) in notes receivables?
SUIG (SUIG) reported increase (decrease) in notes receivables of $0 in Q4 2025.
How has SUIG's increase (decrease) in notes receivables changed year-over-year?
SUIG's increase (decrease) in notes receivables increased by 100.0% year-over-year, from -$62.5K to $0.
What does increase (decrease) in notes receivables mean?
The net change in the balance of formal loan agreements or notes receivable held by the company. This metric reflects the expansion or contraction of the company's lending portfolio and its overall capital deployment strategy. It is a fundamental measure of the company's core business activity as a specialty finance lender.